Clinical trials: Cancer-Related Condition
Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute
CD34+ Transplants for Myeloid Malignancies
This study will evaluate whether processing blood stem cell transplants using an investigational device (the CliniMACS system) results in less complications for patients undergoing transplant for treatment of a blood malignancy…
- Trial name
- NCT05565105
- Testing
- Busulfan, Melphalan, Fludarabine
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Guenther Koehne
Insomnia, Anxiety
Self-acupressure for Cancer-related Symptom Cluster of Insomnia, Depression, and Anxiety: a Feasibility Study
Aim: To assess the acceptability and make estimations about the effectiveness of using self-acupressure to manage insomnia, depression, and anxiety in cancer patients undergoing chemotherapy.
- Conditions
- Insomnia, Anxiety, Depression
- Trial name
- NCT03823456
- Testing
- Self-acupressure
- Where
- 2 sites in Vietnam
- Volunteers
- 114 people
- Sponsor
- The Hong Kong Polytechnic University
Lymphedema, Lymphedema of Upper Arm
The Effect of Complex Decongestive Physiotherapy on Sensory Parameters in Breast Cancer Related Lymphedema.
The aim of this study was to determine the effect of complex decongestive physiotherapy in women with unilateral breast cancer-related lymphedema on sensory parameters.
- Conditions
- Lymphedema, Lymphedema of Upper Arm, Breast Cancer
- Trial name
- NCT04296929
- Testing
- Complex Decongestive Physiotherapy
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Hacettepe University
Heart Failure, Cardiotoxicity
The STOP-MED CTRCD Trial
Cancer therapy-related cardiac dysfunction (CTRCD) is when the heart's ability to pump oxygenated blood to the body is compromised. It is a side effect of cancer therapy which can occur as commonly as in 1 in 5 patients.
- Conditions
- Heart Failure, Cardiotoxicity, Cardiac Toxicity, Antineoplastics Toxicity
- Trial name
- STOP-MED CTRCD (NCT06183437)
- Testing
- Stopping Heart Failure Medication(s)
- Where
- 14 sites in United States, Australia and 4 more
- Volunteers
- 335 people
- Sponsor
- Dinesh Thavendiranathan
Spinal Metastases, Breast Cancer
Pathological Fracture in Potentially Unstable Spinal Metastases of Breast Cancer
The purpose of this study is to identify potential risk factors for and determine the rate of pathological fracture for patients which having spine metastases from breast cancer and be defined as potentially unstable (SINS 7-12)…
- Trial name
- NCT03365973
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Ruijin Hospital
Breast Cancer
Assessment of Breast Cancer-Related Arm Lymphedema
Lymphedema is a serious complication of breast cancer treatment. Reported prevalence of lymphedema following treatment for breast cancer varies, ranging from 7-45%.
- Trial name
- NCT03978754
- Testing
- ICG lymphography、CM、VD、Bioelectrical impedance technology、self-report, Bioelectrical impedance technology、CM
- Where
- China
- Volunteers
- 1,600 people
- Sponsor
- Peking University People's Hospital
Solid Cancer, Gastric (Cardia, Body) Cancer
Impact of CES1 Genotype on Capecitabine Exposure in Cancer Patients
In this study, the drug capecitabine is investigated. Capecitabine is commonly used to treat breast, colon, and stomach cancers. Capecitabine is taken in tablet form.
- Conditions
- Solid Cancer, Gastric (Cardia, Body) Cancer, Esophageal Cancer, Colorectal Cancer (CRC)
- Trial name
- ESCAPE (NCT07114627)
- Testing
- Blood sampling for pharmacokinetics
- Where
- Netherlands
- Volunteers
- 66 people
- Sponsor
- Erasmus Medical Center
Colon Cancer
Impact of Pretreatment With Metformin on Colorectal Cancer Stem Cells (CCSC) and Related Pharmacodynamic Markers
Metformin is drug that is normally used to treat people with diabetes. New research has discovered that metformin may also kill cancer stem cells.
- Trial name
- NCT01440127
- Testing
- Metformin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Tufts Medical Center
Cancer, Cardiotoxicity
BIOMARKER and IMAGING CHARACTERISATION of INFLAMMATORY ATHEROMA in PATIENTS RECEIVING IMMUNOTHERAPY and ANGIOGENESIS INHIBITORS
The advent of immunotherapy (immune checkpoint inhibitors [ICI]) has been an extremely important advancement for cancer treatment in recent decades.
- Conditions
- Cancer, Cardiotoxicity, Atherosclerotic Disease
- Trial name
- BIOCAPRI (NCT06597045)
- Testing
- PET/CT with 18-FDG
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- NHS Greater Glasgow and Clyde
Colorectal Cancer, Metastatic Cancer
Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or Lung
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- ERBIFORT (NCT00557102)
- Testing
- cetuximab, filgrastim, fluorouracil
- Where
- France
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute, France
Breast Cancer, Breast Reconstruction
Immediate Autologous Tissue Breast Reconstruction and Radiotherapy Strategy After Breast Cancer Surgery
This is a prospective, open-label, controlled clinical trial aiming to investigate the optimal sequencing strategy between immediate autologous tissue breast reconstruction and radiotherapy in breast cancer patients.
- Conditions
- Breast Cancer, Breast Reconstruction, Radiotherapy
- Trial name
- NCT07798466
- Testing
- Immediate DIEP flap breast reconstruction, Hypofractionated radiotherapy
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Fudan University
Neoplasm, Breast, Heart Failure
Breast Cancer Long-term Outcomes on Cardiac Functioning: a Longitudinal Study
Rationale: In addition to surgery, effective breast cancer (BC) treatment typically requires chemotherapy, radiotherapy, or both.
- Conditions
- Neoplasm, Breast, Heart Failure, Cardiotoxicity, Ventricular Dysfunction
- Trial name
- BLOC-II (NCT05851053)
- Testing
- Echocardiography
- Where
- Netherlands
- Volunteers
- 455 people, healthy volunteers welcome
- Sponsor
- University Medical Center Groningen
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
This phase I trial studies the side effects and best dose of lenalidomide when given together with cytarabine and idarubicin in treating patients with acute myeloid leukemia.
- Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1
- Trial name
- NCT01132586
- Testing
- Lenalidomide, Cytarabine, Idarubicin
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- National Cancer Institute (NCI)
Cardiac Toxicity, Chemotherapeutic Agent Toxicity
Aerobic Exercise in Patients Receiving Chemotherapy for Cancer
RATIONALE: Aerobic exercise may help prevent side effects caused by chemotherapy and help improve heart health. PURPOSE: This randomized clinical trial is studying the side effects of aerobic exercise and to see how well it works…
- Conditions
- Cardiac Toxicity, Chemotherapeutic Agent Toxicity, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00728429
- Testing
- exercise intervention
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Wake Forest University Health Sciences
Ovarian Cancer
Evaluation of Prognostic Monitoring for Women Who Have Completed Standard Treatment for Ovarian Cancer
The relationship between immune inflammation-related protein complexes inblood and recurrence or metastasis of ovarian cancer will be studied
- Trial name
- NCT05410015
- Testing
- Normal clinical treatment without intervention
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Impaired Cognition, Chemo-brain
Chemotherapy-induced Cognitive and Brain Changes in Older Adults With Breast Cancer
This research study evaluates the effect of chemotherapy on cognition (thinking) and the brain in people with breast cancer.
- Conditions
- Impaired Cognition, Chemo-brain, Breast Cancer
- Trial name
- NCT02290834
- Testing
- Cognitive, functional and subjective assessments, MRI, PET Scan
- Where
- 2 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Patients With Non-small Cell Lung Cancer (NSCLC) and Pleural Mesothelioma and Treated With a Pemetrexed-based Chemotherapy
Association Between Proton Pump Inhibitors and Hematologic Toxicity of Pemetrexed
Pemetrexed is a multi-folate inhibitor approved in the treatment of non-small cell lung cancer (NSCLC) and pleural mesothelioma.
- Trial name
- IPPEM (NCT03537833)
- Testing
- pemetrexed-related hematological toxicity
- Where
- France
- Volunteers
- 172 people
- Sponsor
- CHU de Reims
Neurofibromatosis 2, Vestibular Schwannoma
Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors
In this research study the researchers want to learn more about the effects (both good and bad) the study drug selumetinib has on participants with neurofibromatosis type II (NF2) related tumor.
- Conditions
- Neurofibromatosis 2, Vestibular Schwannoma, Meningioma, Ependymoma
- Trial name
- SEL-TH-1601 (NCT03095248)
- Testing
- Selumetinib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Urethral Internal Sphincter Morphology, Benign Prostatic Hyperplasia
MRI-DTI Assessment of Urethral Internal Sphincter Ring and Prostate Base Morphology
This is a single-center, observational imaging study designed to evaluate the in vivo morphology of the male urethral internal sphincter ring using magnetic resonance diffusion tensor imaging (MRI-DTI) fiber tracking and to…
- Conditions
- Urethral Internal Sphincter Morphology, Benign Prostatic Hyperplasia, Prostate Cancer
- Trial name
- NCT07694752
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Jiangsu Taizhou People's Hospital
Unresectable Breast Cancer, Metastatic Breast Cancer
HER-TEMPO - Real World Treatment-related Outcomes on T-DXd in Canada
Trastuzumab deruxtecan (T-DXd) has been studied in multiple global prospective DESTINY-Breast trials and has a marketing authorization from Health Canada for patients with HER2-positive metastatic breast cancer (mBC) and HER2-low…
- Conditions
- Unresectable Breast Cancer, Metastatic Breast Cancer, HER2-low Expressing Breast Cancer, HER2-positive Breast Cancer
- Trial name
- HER-TEMPO (NCT06386263)
- Testing
- Trastuzumab deruxtecan
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.